13 - Bronchiectasis and NTMs

Thursday, October 17, 2024

8:00 AM – 9:00 AM US PT

Location: 515 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1 hours of MOC Credit
CNE Credits: Maximum of 1 hours of ANCC Credit
ACPE Credits: ACPE 1 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

MD

Mahalia Dessruisseaux
Luiz Bermudez, MD

Professor
Oregon State University
Corvallis, OR, United States

Faculty(s)

AO

Anne O'Donnell, MD (she/her/hers)

Professor of Medicine
Georgetown University
Washington, DC, United States
Charles Daley, MD (he/him/his)

Chief, Division of Mycobacterial & Respiratory Infections  Professor, Medicine 
National Jewish Health
Denver , CO, United States

Disclosure(s):

Mahalia Dessruisseaux: No financial relationships to disclose

Luiz Bermudez, MD: No financial relationships to disclose

Anne O'Donnell, MD: Armata Pharmaceuticals, Inc: Grant/Research Support (Ongoing); Boeringer Ingelheim: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); MannKind: Grant/Research Support (Ongoing); Zambon: Advisor/Consultant (Terminated, October 2, 2024), Grant/Research Support (Terminated, October 2, 2024)

Charles L. Daley, MD: AN2 Therapeutics, Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Bill & Melinda Gates Foundation: Advisor/Consultant (Ongoing); Bugworks Research, Inc.: Grant/Research Support (Terminated, June 30, 2024); Galapagos NV: Advisor/Consultant (Ongoing); Genentech: Advisor/Consultant (Ongoing); Hyfe: Advisor/Consultant (Ongoing); Insmed Inc: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Juvabis: Grant/Research Support (Ongoing); MannKind: Advisor/Consultant (Ongoing); Matinas Biopharma,: Advisor/Consultant (Ongoing); NobHill Therapeutics: Advisor/Consultant (Ongoing); Otsuka Pharmaceuticals: Advisor/Consultant (Terminated, July 31, 2024); Paratek Pharmaceuticals: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer, Inc.: Advisor/Consultant (Ongoing); Spero Therapeutics,: Advisor/Consultant (Ongoing); Zambon: Advisor/Consultant (Ongoing)

Learning Objectives:

At the conclusion of this session, participants will be able to:

investigate the risk of ntm infection;
explain the parameters associated with the progression of the disease;
describe treatment of this population of patients;
analyze the follow-up.

Presentations:

8:00 AM – 8:30 AM US PT

Bronchiectasis Update
Speaker: Anne O'Donnell, MD (she/her/hers) – Georgetown University
8:30 AM – 9:00 AM US PT

Current Treatment Approach for NTM lung Infection
Speaker: Charles L. Daley, MD (he/him/his) – National Jewish Health